Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Reexamination Certificate
2006-09-15
2010-10-05
Vogel, Nancy (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
C435S477000
Reexamination Certificate
active
07807444
ABSTRACT:
A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.
REFERENCES:
patent: 4190495 (1980-02-01), Curtiss, III
patent: 4654307 (1987-03-01), Morgan
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4761367 (1988-08-01), Edgell et al.
patent: 5198343 (1993-03-01), DeGryse
patent: 5434065 (1995-07-01), Mahan et al.
patent: 5510099 (1996-04-01), Short et al.
patent: 5656481 (1997-08-01), Baetge et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5700657 (1997-12-01), Beaudry et al.
patent: 5714323 (1998-02-01), Ohshima et al.
patent: 5773246 (1998-06-01), Keene et al.
patent: 5851808 (1998-12-01), Elledge et al.
patent: 5859208 (1999-01-01), Fiddes et al.
patent: 5874259 (1999-02-01), Szybalski
patent: 5919663 (1999-07-01), Brey et al.
patent: 5955056 (1999-09-01), Short et al.
patent: 5985644 (1999-11-01), Roseman et al.
patent: 6254874 (2001-07-01), Mekalanos et al.
patent: 6573100 (2003-06-01), Seeber et al.
patent: 6977174 (2005-12-01), Crouzet et al.
patent: 7279313 (2007-10-01), Soubrier
patent: 7364894 (2008-04-01), Soubrier
patent: WO 95/30762 (1995-11-01), None
patent: WO 96/01899 (1996-01-01), None
patent: WO 2004/108167 (2004-12-01), None
Meinnel et al., J. Bacteriology, Apr. 1992, vol. 174, No. 7, pp. 2323-2331.
Grayeb et al., DNA, 5, 93-99, 1986.
Normanly et al., Proc. Natl. Acad. Sci. USA 83:6548-6552, 1986.
Panicker et al., J. Bacteriol., 162(2):584-590 (1985).
Anderson, W. French, Human gene therapy, Nature, 392:25-28.
Dalyot et al., Efficient Transfer Of The Complete Human Beta-Globin Gene Into Human And Mouse Hemopoeitic Cells Via SV40 Pseudovirions, Gene Transfer & Gene Therapy, 47-56 (1989).
Filutowicz et al., J. Cell Sci. Suppl. 7, 15-31 (1987).
Flensburg et al., J. Mol. Biol., 195:439-445 (1987).
Gluzman, SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants, Cell, 23:175-182 (1981).
Herrero et al., Transposon Vectors Containing Non-Antibiotic Resistance Selection Markers for Cloning and Stable Chromosomal Insertion of Foreign Genes in Gram-Negative Bacteria, Journal of Bacteriology, 172(11):6557-6567 (1990).
Inuzuka et al., An initiator protein for plasmid R6K DNA replication Mutations affecting the copy-number control, FEBS Letters 228(1):7-11 (1988).
Larsen et al., Low-copy-number plasmid-cloning vectors amplifiable by derepression of an inserted foreign promoter, Gene, 28:45-54 (1984).
Metcalf et al., Use of the rep technique for allele replacement to construct newEscherichia colihosts for maintenance of R6Ky origin plasmids at different copy numbers, Gene, 138:1-7 (1994).
Posfai et al., NAR 22(12):2392-2398 (1994).
Rusconi et al., A novel expression assay to study transcriptional activators, Gene, 89:211-221 (1990).
Scott, June Rothman, Regulation of Plasmid Replication, Microbiological Reviews, 48(1):1-23 (Mar. 1984).
Summers et al., Multimerization of High Copy Number Plasmids Causes Instability: ColE1 Encodes a Determinant Essential for Plasmid Monomerization and Stability, Cell, 36:1097-1103 (1984).
Vasavada et al., A contingent replication assay for the detection of protein-protein interactions in animal cells, Proc. Natl. Acad. Sci., USA, 88:10686-10690 (1991).
Winnacker, E.L.,From Genes to Clones, 132-138 (1987).
Koons et al., “Characterization of pPvu1, the autonomous plasmid from Proteus vulgaris that carries the genes of the Pvu11 restriction-modiciation system,” Gene, 157:73-79, 1995.
Baum et al., “Novel Cloning Vectors forBacillus thuringiensis,” Applied and Environmental Microbiology, 56:3420, 1990.
Penfold et al., “An improved suicide vector for construction of chromosomal insertion mutations in bacteria,” Gene, 18:145-146, 1992.
Bergemann et al., “Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination,” Nucleic Acids Research, 23(21):4451-4456, 1995.
Gage et al., “A Cell-Free Recombination. System for Site-Specific Integration of Multigenic Shuttle Plasmids into the Herpes Simplex Virus Type 1 Genome,” Journal of Virology, 66(9):5509-5515, 1992.
Hanzlik et al., “A small plasmid for recombination-based screening,” Gene, 122:171-174, 1992.
Metzger et al., “Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase,” Proc. Natl. Acad. Sci. USA, 92:6991-6995, 1995.
Stewart et al., “Plasmids for recombination-based screening,” Gene, 106:97-101, 1991.
Kelley et al., “Conformational Changes Induced by Integration Host Factor at Origin γof R6K and Copy Number Control,” The Journal of Biological Chemistry, 266(24):15924-15937, 1991.
Carriére et al., “Optimization of plasmids for gene delivery,” STP Pharma Sciences, 2001, vol. 11 No. 1, pp. 5-10.
Presentation entitled “Gene Therapy for Ischemic Disease,” by Beatrice Cameron, Sep. 23-27, 1998, Cold Spring Harbor Laboratory, New York.
Presentation entitled “FGF-1 Gene Delivery: Preliminary Clinical Results in Peripheral Vascular Disease,” by Richard Pilsudski, Third Annual Angiogenesis Mini-Summit, New Orleans, La., Nov. 11, 2000.
Presentation entitled Arteriopathie des Membres Inferieurs: Quoi de neuf 2001 Therapie Genique, by Richard Pilsudski, Journees Internationales d'Angeiologie, Paris, Jan. 12-13, 2001.
Presentation entitled “Strategies for Clinical Application of Angiogenesis-Myogenesis Research,” by Richard Pilsudski, 7thLocal Drug Delivery Meeting and Cardiovascular Course on Radiation and Molecular Strategies, Geneva, Switzerland, Jan. 25-27, 2001.
Presentation entitled Angiogenesis: Promoting Angiogenesis: Angiogenesis Gene Therapy for Peripheral Vascular Disease, by Richard Pilsudski, Institut Pasteur Euroconferences, Paris, Mar. 8-9, 2001.
Presentation entitled “Large-Scale Purification of Plasmid DNA b Triplex Affinity Chromotography,” by Francis Blanche, Recovery X, Cancun, Jun. 3-8. 2001.
Presentation entitled “Therapeutic Angiogenesis in Peripheral Vascular Disease—Final Results of the Phase I Trial on FGF-1 Gene Delivery,” by Richard Pilsudski, Angiogenesis & DMR, Washington., Jun. 21-22, 2001.
Presentation entitled Purification of Plasmid DNA by Triplex Affinity Chromotography, by Francis Blanche, Downstream Processing of Nucleic Acids, Sep. 17-18, 2001.
Presentation entitled Therapeutische Angiogenese: Clinical Results of NV1FGF Gene Therapy in Chronic Limb Ischemia, by Richard Pilsudski, Angio 2001, Nov. 29-Dec. 1, 2001, Bern.
Presentation entitled “pCOR Gene Therapy Plasmid: Improvements of Existing Technology,” by Fabienne Soubrier, ESGT, approximate date Oct. 13, 2002.
Presentation entitled “Final Results of a FGF-1 Gene Therapy Clinical Trial in Patients with Critical Limb Ischemia,” by Marie-Helene Francois, 17thInternational Congress on Thrombosis, Oct. 30, 2002, Bologna, Italy.
Presentation entitled A Phage 1 Study to Evaluate the Safety and Biological Activity of Plasmid DNA Encoding FGF1 in Patients with Severe Peripheral Artery Occlusive Disease, by Michael Coleman, Angiogenesis: Gene Therapy of Cardiovascular Diseases with Angiogenic Growth Factors, SMI, Feb. 17-18, 2003, The Hatton, London.
Presentation entitled “Quality Control of NV1FGF Plasmid DNA for PAD Gene Therapy,” by Didier Faucher, International Symposium organized by EDQM on Standardization and Quality Control Cell and Gene Therapy Products, EDQM meeting, Feb. 24-25, 2003, Strasbourg.
Faucher et al., “Quality Control of NV1FGF Plasmid DNA for PAD Gene Therapy,” S
Centelion
Finnegan Henderson Farabow Garrett & Dunner LLP
Vogel Nancy
LandOfFree
Circular DNA molecule having a conditional origin of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Circular DNA molecule having a conditional origin of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Circular DNA molecule having a conditional origin of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170357